<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433641</url>
  </required_header>
  <id_info>
    <org_study_id>06-003371</org_study_id>
    <secondary_id>NIH DK67071</secondary_id>
    <nct_id>NCT00433641</nct_id>
  </id_info>
  <brief_title>Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes</brief_title>
  <official_title>Pharmacogenomics of Weight Loss With Sibutramine in Obese and Overweight Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Control of food intake, size and frequency of meals are critical to the development of&#xD;
      obesity. The stomach signals feelings of fullness after a meal and therefore plays a role in&#xD;
      control of calorie intake. It is unclear whether the approved appetite reducing drug&#xD;
      sibutramine changes the function of the stomach. Differences in the way individuals respond&#xD;
      to treatment with the appetite suppressant sibutramine may also explain why some people lose&#xD;
      weight while others do not.&#xD;
&#xD;
      In a previous study of 48 overweight or obese participants, we preliminarily observed that&#xD;
      variation in the gene for the promoter of the serotonin transporter protein was significantly&#xD;
      associated with degree of weight loss.&#xD;
&#xD;
      This new single center clinical study aims to evaluate the effects of the FDA-approved&#xD;
      appetite suppressing medication, sibutramine (MERIDIA)on weight loss and stomach emptying in&#xD;
      patients who are overweight or obese. The effect of individual differences in inherited genes&#xD;
      that modify serrotonin and noradrenergic receptors on weight reduction with sibutramine will&#xD;
      be tested.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:. Genetic variations are potentially key to inter-individual differences in&#xD;
      responses to treatment with the appetite suppressant sibutramine.&#xD;
&#xD;
      Overall Aims: To evaluate influence of genetic variation in candidate adrenergic and&#xD;
      serotonergic control mechanisms on weight loss and gastric emptying response to sibutramine&#xD;
      in obesity.&#xD;
&#xD;
      Methods: 180 overweight or obese (respectively BMI of 25-29.9 or 30 kg/m2) people treated&#xD;
      with sibutramine (10 or 15 mg/day) or placebo for 12 wks. We shall collect DNA from venous&#xD;
      blood sample at study entry, and use SERT-P genotype at baseline to stratify patients&#xD;
      according to LL vs LS/SS genotype in both obese and overweight groups. The primary outcome&#xD;
      measurement will be the association of clinical response (weight loss) and the influence of&#xD;
      SERT-P and 2-MSP variation. A secondary outcome for descriptive purposes is the gastric&#xD;
      emptying response to sibutramine treatment. Gastric emptying of solids will be measured using&#xD;
      stable isotope method.&#xD;
&#xD;
      Anticipated Results: SERT-P genotype is significantly associated with the magnitude of weight&#xD;
      loss in obese and overweight individuals.&#xD;
&#xD;
      Significance: Our study will provide the first evidence of the pharmacogenomic effects of&#xD;
      sibutramine on weight loss in obesity and appraise the association of weight loss with change&#xD;
      in gastric emptying.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Association of weight loss with candidate genotypes</measure>
    <time_frame>2006-2007</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>T1/2 gastric emptying of solids</measure>
    <time_frame>2006-2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body composition (fat)</measure>
    <time_frame>2006-2007</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sibutramine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sibutramine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sibutramine</intervention_name>
    <description>placebo</description>
    <arm_group_label>1</arm_group_label>
    <other_name>meridia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sibutramine</intervention_name>
    <description>oral 15 mg sibutramine once per day</description>
    <arm_group_label>3</arm_group_label>
    <other_name>MERIDIA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sibutramine</intervention_name>
    <description>oral sibutramine 10 mg once per day</description>
    <arm_group_label>2</arm_group_label>
    <other_name>MERIDIA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal weight, overweight and obese subjects with BMI&gt; 18 Kg/m2 residing in Olmsted&#xD;
             County, MN: Otherwise healthy individuals who are not currently on treatment for&#xD;
             cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, neurological,&#xD;
             endocrine (other than hyperglycemia not requiring medical therapy) and unstable&#xD;
             psychiatric disease.&#xD;
&#xD;
          -  Age: 18-65 years&#xD;
&#xD;
          -  Gender: Men or women. Women of childbearing potential will have negative pregnancy&#xD;
             test within 48 h of enrollment and before each radiation exposure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Weight exceeding 300 pounds or 137 kilograms (due to limitations regarding SPECT&#xD;
             imaging studies).&#xD;
&#xD;
          -  Abdominal surgery other than appendectomy, Caesarian section or tubal ligation.&#xD;
&#xD;
          -  Positive history of chronic gastrointestinal diseases, systemic disease that could&#xD;
             affect gastrointestinal motility or use of medications that may alter gastrointestinal&#xD;
             motility, appetite or absorption e.g., orlistat (Xenical&amp;#61650;).&#xD;
&#xD;
          -  Significant psychiatric dysfunction based upon screening with the Hospital Anxiety and&#xD;
             Depression Scale [HADS] self-administered alcoholism screening test (substance abuse)&#xD;
             and the questionnaire on eating and weight patterns (binge eating disorders and&#xD;
             bulimia). If such a dysfunction is identified by a HADS score &gt;8 or difficulties with&#xD;
             substance or eating disorders, the participant will be excluded and given a referral&#xD;
             letter to his/her primary care doctor for further appraisal and follow-up.&#xD;
&#xD;
          -  Intake of medication, whether prescribed or OTC medication (except multivitamins)&#xD;
             within 7 days of the study. Exceptions are birth control pill, estrogen replacement&#xD;
             therapy, and thyroxine replacement.&#xD;
&#xD;
          -  Concomitant use of MAOI inhibitors and other centrally acting appetite suppressants&#xD;
             (since this would make them ineligible for sibutramine treatment).&#xD;
&#xD;
          -  Hypersensitivity to sibutramine (since this would make them ineligible for sibutramine&#xD;
             treatment).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael L. Camilleri, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>February 8, 2007</study_first_submitted>
  <study_first_submitted_qc>February 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <last_update_submitted>March 10, 2011</last_update_submitted>
  <last_update_submitted_qc>March 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Michael Camilleri</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>pharmacogenetics</keyword>
  <keyword>sibutramine</keyword>
  <keyword>adrenergic</keyword>
  <keyword>serotonergic</keyword>
  <keyword>body composition</keyword>
  <keyword>gastric emptying</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sibutramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

